Compare Neurocrine Biosciences Inc (NBIX) vs Blue Owl Capital Inc. Class A Common Stock (OWL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Blue Owl Capital Inc. Class A Common Stock — how do they compare? Neurocrine Biosciences Inc trades at $135.83 (market cap $14.37B), while Blue Owl Capital Inc. Class A Common Stock trades at $8.81 (market cap $6.35B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.3× Blue Owl Capital Inc. Class A Common Stock's market cap, and Blue Owl Capital Inc. Class A Common Stock pays a 9.8% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 24 Days and Blue Owl Capital Inc. Class A Common Stock for 0 Days on average.
| NBIX | OWL | |
|---|---|---|
Market Cap | $14.37B | $6.35B |
Volume | 1,081,559 | 15,716,423 |
Sector | Health | Financials |
52-Week High | $185.50 | $17.17 |
52-Week Low | $123.10 | $8.23 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $14.38B | $10.53B |
Dividend Yield | — | 9.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $135.13, down 4.41% over 24 hours amid a broader bearish technical signal, though key moving averages and oscillators show mixed signals. Fundamentally, the company demonstrates robust health with a 97.91% gross profit margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 against a $1.85 expectation. Recent news highlights pipeline advancements, including presentations on Prader-Willi syndrome research and executive appointments, supporting long-term growth narratives beyond its flagship product INGREZZA.
The investment outlook for NBIX is positive, driven by strong analyst consensus with a $204.18 price target and 86.49% buy ratings, reflecting confidence in revenue growth and pipeline diversification. Key risks include execution challenges in commercializing new products and potential pricing pressures on INGREZZA post-2029. Investors should weigh the company's high profitability and cash flow generation against these sector-specific headwinds.
Blue Owl Capital (OWL) trades at $9.29, down 0.54% on the day, with neutral technical indicators showing support at $9 and resistance at $10. The company reported mixed quarterly earnings, beating expectations in Q4 2025 and Q2 2026 but missing in Q1 2026, with Q3 2026 results pending. Revenue growth remains steady at $2.9B in 2025, projected to $3.0B in 2026, though net margins are thin at 2.71%. Analyst sentiment is positive with 63% buy ratings and a $11.01 consensus target, but private credit fund redemptions and loan quality concerns present headwinds.
OWL offers value at a discount to analyst targets with strong institutional backing, but investors face risks from high P/E valuation (77.42), exposure to private credit volatility, and competitive pressures. The stock's 9.8% dividend yield and embedded fee growth from $31.1B in committed capital support upside, though execution on portfolio quality and redemption management will dictate near-term performance. Neutral outlook with cautious optimism pending Q3 earnings clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Blue Owl Capital Inc. Class A Common Stock
Blue Owl Capital Inc. is an alternative asset manager that invests across credit, real assets, and GP strategic capital strategies, providing private capital solutions to businesses and to institutional and individual investors.
Read more on OWL →
